Analysts Expect Boston Scientific to Bounce Back
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: Yahoo Finance
- Price Recovery Outlook: Boston Scientific Corporation (NYSE:BSX) has seen its stock price drop over 52% year-to-date, yet analysts anticipate a more than 65% upside from current levels, indicating strong market confidence in its future performance.
- Buy Rating Maintained: TD Cowen analyst Josh Jennings has maintained a Buy rating on Boston Scientific with a price target of $61, reflecting confidence in the company's resilience despite facing near-term pressures.
- Financial Guidance Adjustments: The analyst noted that while earnings expectations have drifted down recently, this makes the lower end of the fiscal Q2 2026 revenue and EPS guidance more achievable, suggesting a reassessment of the company's performance outlook.
- Organic Growth Targets: Despite underperformance in US Watchman sales and other franchises, management continues to expect total organic growth to remain within targeted ranges for both Q2 and the full year 2026, highlighting the company's ongoing growth potential in the medical device sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 45.140
Low
94.00
Averages
108.14
High
132.00
Current: 45.140
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS's Top Stock Picks for Q3 2026
- Vertiv Stock Surge: Vertiv's stock has surged 92% this year, establishing itself as a favored AI infrastructure play, with UBS analysts noting its strong cash flow return on investment and high asset growth rates, suggesting that its upward value creation trajectory remains intact.
- Nvidia Economic Profit: Although Nvidia's stock is only up 6% in 2026, UBS still regards it as an exemplary wealth compounder, forecasting a doubling of its economic profit by 2027, with analysts' consensus indicating over 50% upside potential from current levels.
- Ralph Lauren Recovery: Ralph Lauren's stock has rallied 13% this year, with UBS highlighting a sharp rebound in cash flow return on investment from pandemic lows, projecting a decade-high of 15%, while the market remains optimistic about its long-term growth potential with a target price suggesting an additional 7% upside.
- Diverse Stock Picks: UBS's list also includes Spotify, Boston Scientific, Target, and Coca-Cola, reflecting confidence in a diversified investment strategy aimed at capitalizing on opportunities arising from market recovery.
See More
Analysts Expect Boston Scientific to Bounce Back
- Price Recovery Outlook: Boston Scientific Corporation (NYSE:BSX) has seen its stock price drop over 52% year-to-date, yet analysts anticipate a more than 65% upside from current levels, indicating strong market confidence in its future performance.
- Buy Rating Maintained: TD Cowen analyst Josh Jennings has maintained a Buy rating on Boston Scientific with a price target of $61, reflecting confidence in the company's resilience despite facing near-term pressures.
- Financial Guidance Adjustments: The analyst noted that while earnings expectations have drifted down recently, this makes the lower end of the fiscal Q2 2026 revenue and EPS guidance more achievable, suggesting a reassessment of the company's performance outlook.
- Organic Growth Targets: Despite underperformance in US Watchman sales and other franchises, management continues to expect total organic growth to remain within targeted ranges for both Q2 and the full year 2026, highlighting the company's ongoing growth potential in the medical device sector.
See More
Jim Cramer's Insights on Various Stocks
- NioCorp Outlook: Jim Cramer views NioCorp as too speculative, favoring MP Materials, which has government backing, indicating stronger market confidence and stability.
- SoFi Investment Opportunity: Cramer highlights that SoFi's stock price around $18 is a buying opportunity, suggesting optimism about its future performance, which may attract more investor interest.
- Rivian Financial Concerns: Cramer expresses concerns over Rivian's financial performance, noting excessive losses and advising caution for investors, which could lead to further declines in stock price.
- SoundHound AI Risks: Cramer gives a very negative assessment of SoundHound AI, labeling it a “meme stock” and recommending selling, reflecting high uncertainty in the market regarding such stocks.
See More
Adobe and Others Hit Annual Lows Amid Analyst Downgrades
- Adobe Stock Decline: Adobe (ADBE) shares fell to $196.90 during intraday trading on Friday, marking an eight-year low primarily due to concerns over AI competition and the departure of its CFO, despite reporting Q2 revenue of $6.62 billion, a 13% year-over-year increase, exceeding expectations.
- Analyst Downgrades Impact: Freedom Broker analyst downgraded Adobe from ‘Buy’ to ‘Hold’ and slashed the price target by over 50% to $250, citing a shift in growth quality and management's trade-off of near-term subscription revenue for customer acquisition, indicating weakened market confidence in Adobe's future.
- Chewy Faces Challenges: Chewy (CHWY) shares slid to a fresh 52-week low of $18.22 on Friday; despite reporting revenue and earnings growth in Q1, management warned of a challenging consumer pet environment, prompting analysts to cut price targets, with Goldman Sachs lowering it to $34 while maintaining a ‘Buy’ rating.
- Boston Scientific Stock Drop: Boston Scientific (BSX) shares fell to an annual low of $45.99 on Friday after receiving multiple price target cuts, with Piper Sandler lowering its target to $65, highlighting challenges from deceleration in key drivers and a more conservative outlook for 2027 growth estimates.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
UBS's Top Stock Picks for Q3 2026
- Vertiv Stock Surge: Vertiv's stock has surged 92% this year, establishing itself as a favored AI infrastructure play, with UBS analysts noting its strong cash flow return on investment and high asset growth rates, suggesting that its upward value creation trajectory remains intact.
- Nvidia Economic Profit: Although Nvidia's stock is only up 6% in 2026, UBS still regards it as an exemplary wealth compounder, forecasting a doubling of its economic profit by 2027, with analysts' consensus indicating over 50% upside potential from current levels.
- Ralph Lauren Recovery: Ralph Lauren's stock has rallied 13% this year, with UBS highlighting a sharp rebound in cash flow return on investment from pandemic lows, projecting a decade-high of 15%, while the market remains optimistic about its long-term growth potential with a target price suggesting an additional 7% upside.
- Diverse Stock Picks: UBS's list also includes Spotify, Boston Scientific, Target, and Coca-Cola, reflecting confidence in a diversified investment strategy aimed at capitalizing on opportunities arising from market recovery.
See More
Analysts Expect Boston Scientific to Bounce Back
- Price Recovery Outlook: Boston Scientific Corporation (NYSE:BSX) has seen its stock price drop over 52% year-to-date, yet analysts anticipate a more than 65% upside from current levels, indicating strong market confidence in its future performance.
- Buy Rating Maintained: TD Cowen analyst Josh Jennings has maintained a Buy rating on Boston Scientific with a price target of $61, reflecting confidence in the company's resilience despite facing near-term pressures.
- Financial Guidance Adjustments: The analyst noted that while earnings expectations have drifted down recently, this makes the lower end of the fiscal Q2 2026 revenue and EPS guidance more achievable, suggesting a reassessment of the company's performance outlook.
- Organic Growth Targets: Despite underperformance in US Watchman sales and other franchises, management continues to expect total organic growth to remain within targeted ranges for both Q2 and the full year 2026, highlighting the company's ongoing growth potential in the medical device sector.
See More
Jim Cramer's Insights on Various Stocks
- NioCorp Outlook: Jim Cramer views NioCorp as too speculative, favoring MP Materials, which has government backing, indicating stronger market confidence and stability.
- SoFi Investment Opportunity: Cramer highlights that SoFi's stock price around $18 is a buying opportunity, suggesting optimism about its future performance, which may attract more investor interest.
- Rivian Financial Concerns: Cramer expresses concerns over Rivian's financial performance, noting excessive losses and advising caution for investors, which could lead to further declines in stock price.
- SoundHound AI Risks: Cramer gives a very negative assessment of SoundHound AI, labeling it a “meme stock” and recommending selling, reflecting high uncertainty in the market regarding such stocks.
See More
Adobe and Others Hit Annual Lows Amid Analyst Downgrades
- Adobe Stock Decline: Adobe (ADBE) shares fell to $196.90 during intraday trading on Friday, marking an eight-year low primarily due to concerns over AI competition and the departure of its CFO, despite reporting Q2 revenue of $6.62 billion, a 13% year-over-year increase, exceeding expectations.
- Analyst Downgrades Impact: Freedom Broker analyst downgraded Adobe from ‘Buy’ to ‘Hold’ and slashed the price target by over 50% to $250, citing a shift in growth quality and management's trade-off of near-term subscription revenue for customer acquisition, indicating weakened market confidence in Adobe's future.
- Chewy Faces Challenges: Chewy (CHWY) shares slid to a fresh 52-week low of $18.22 on Friday; despite reporting revenue and earnings growth in Q1, management warned of a challenging consumer pet environment, prompting analysts to cut price targets, with Goldman Sachs lowering it to $34 while maintaining a ‘Buy’ rating.
- Boston Scientific Stock Drop: Boston Scientific (BSX) shares fell to an annual low of $45.99 on Friday after receiving multiple price target cuts, with Piper Sandler lowering its target to $65, highlighting challenges from deceleration in key drivers and a more conservative outlook for 2027 growth estimates.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
